PD30-03 PREDICTING RESPONSE TO INTRAVESICAL BCG IN HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER USING AN ARTIFICIAL INTELLIGENCE-POWERED PATHOLOGY ASSAY: DEVELOPMENT AND VALIDATION IN AN INTERNATIONAL 12 CENTER COHORT

Yair Lotan(Southwestern Medical Center), Stephen B. Williams(Cedars-Sinai Medical Center), Andrew Redfern(Uppsala University Hospital), John A. Taylor(UConn Health), Lisa Spalding, Mario I. Fernández(Clínica Alemana), Vrishab Krishna(Vale (Brazil)), Thomas Gerald, L. Baekelandt(KU Leuven), Dickon Hayne(The University of Western Australia), Bryn Launer(Vanderbilt University Medical Center), Patrick J. Hensley(University of Kentucky), Anand Rajan(Johns Hopkins Medicine), Derek B. Allison(University of Kentucky), Viswesh Krishna(Vale (Brazil)), Vivek Nimgaonkar, Damir Vrabac(University of Pittsburgh Medical Center), Jay B. Shah(The University of Texas MD Anderson Cancer Center), Eugene Shkolyar(Stanford University), Jennifer Gordetsky(Bipar), Dattatraya Patil(Emory University), Vikram M. Narayan(Emory University), Louis Vaickus(Boston University), Waleed M. Abuzeid(University of Washington), Marcela Schultz, Courtney Stewart, Ameer Hamza, Vignesh T. Packiam(Rutgers, The State University of New Jersey), Sam S. Chang(Memorial Sloan Kettering Cancer Center), Snehal Sonawane(Rutgers, The State University of New Jersey), Daniel L. Miller(Augusta University), Anirudh Joshi, Ekin Tiu, S. Singhi, Michael A. O’Donnell(University of Iowa Health Care)
The Journal of Urology
April 15, 2024
Cited by 2


Related Papers